Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis

EJNMMI Research

Table 1 Clinical characteristics for each patient before endoradiotherapy with amino acid co-administration

Patient	Primary tumor	ERT	Sex	Age (a)	Weight (kg)	Height (m)	GFR (CKD-EPI)	KDIGO Grade of CKD	MAG 3 clearance ml/min/1.73 qm BSA	Creatinine (mg/dl)	BUN (mg/dl)
1	NET	PRRT	F	45	50	1.62	105	G1	236	0.7	14
2	NET	PRRT	M	57	58	1.71	74	G2	195	1.0	21
3	Prostate cancer	RLT	M	66	74	1.76	93	G1	178	0.8	16
4	Prostate cancer	RLT	M	76	90	1.84	83	G2	178	0.9	14
5	Prostate cancer	RLT	M	64	71	1.74	90	G1	252	0.9	17
6	Prostate cancer	RLT	M	73	75	1.74	60	G2	157	1.2	13
7	Prostate cancer	RLT	M	62	85	1.78	91	G1	269	0.9	13
8	Prostate cancer	RLT	M	73	89	1.75	74	G2	175	1.0	13
9	NET	PRRT	M	63	130	1.72	91	G1	253	0.9	21
10	NET	PRRT	M	71	102	1.84	60	G2	187	1.2	12
11	Prostate cancer	RLT	M	72	67	1.74	67	G2	175	1.1	28
12	NET	PRRT	F	54	63	1.76	84	G2	257	0.8	14
13	Prostate cancer	RLT	M	77	64	1.71	72	G2	224	1.0	18
14	Prostate cancer	RLT	M	76	66	1.89	92	G1	143	0.7	14
15	Prostate cancer	RLT	M	73	84	1.84	74	G2	208	1.0	17
16	Prostate cancer	RLT	M	57	87	1.90	112	G1	251	0.6	12
17	NET	PRRT	M	69	95	1.86	76	G2	233	1.0	20
18	NET	PRRT	M	73	86	1.80	60	G2	132	1.2	21
19	NET	PRRT	M	53	80	1.76	86	G2	211	1.0	17
20	NET	PRRT	M	59	85	1.77	55	G3	122	1.4	15
21	Prostate cancer	RLT	M	73	78	1.80	49	G3	129	1.4	32
22	Thyroid	PRRT	F	62	52	1.57	93	G1	192	0.7	9
min.				45	50	1.57	49		122	0.6	9
max.				77	130	1.90	112		269	1.4	32
mean				66	79	1.77	79		201	1.0	17
median				68	79	1.76	80		195	1.0	16
SD				08	17	0.08	16		43	0.2	5.3

NET Neuroendocrine tumor, GFR glomerular filtration rate, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, MAG3 mercapto-acetyltriglycine, KDIGO Kidney Disease—Improving Global Outcomes, BUN Blood urea nitrogen